title: The efficacy of retrograde infusion with LY231617 in a rat middle cerebral artery occlusion model.
abstract: OBJECTIVE
  We examined the efficacy of the antioxidant LY231617 administered five hours following middle cerebral artery (MCA) occlusion in rats.
  
  
  METHODS
  The treatment was contrived for a two hour interval. Group A (n = 16) was left untreated. Group B (n = 16) received an intravenous infusion of LY231617. Group C (n = 16) received saline (86 microliters/min) by retrograde infusion of the cerebral vein (RICV). Group D (n = 22) was administered LY231617 (10mg/kg/2 hr) in saline (86 microliters/min) by RICV. Local cerebral blood flow with [14C]-iodoantipyrine and blood-brain transfer constant with 14C-alpha-amino-isobutyric acid were examined. Early ischemic damage was histologically examined with cresyl violet and Luxol fast blue and with triphenyl-tetrazolium chloride.
  
  
  RESULTS
  The results revealed a marked increase in local cerebral blood flow (over 600%, p < 0.01) after RICV with LY231617, with a significant improvement of BBB permeability in rats from group D. Ischemic brain damage measured with Luxol fast blue and triphenyl-tetrazolium chloride methods showed a significant improvement (50-91%) of ischemic damage in group D, as compared to groups B and C.
  
  
  CONCLUSIONS
  Retrograde infusion of the cerebral vein with LY231617 resulted in a significant amelioration at seven hours post MCA occlusion.
authors.affiliation: Neuroisotope Laboratory, Mc Gill University, Montreal, Quebec, Canada.
authors.forename: N
authors.initials: N
authors.lastname: Inoue
authors.forename: Y L
authors.initials: YL
authors.lastname: Yamamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Ito
authors.forename: J A
authors.initials: JA
authors.lastname: Clemens
authors.forename: J K
authors.initials: JK
authors.lastname: Panetta
authors.forename: M
authors.initials: M
authors.lastname: Diksic
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001345:Autoradiography; D002545:Brain Ischemia / Q000188:drug therapy*; D002084:Butylated Hydroxytoluene / Q000031:analogs & derivatives* / Q000494:pharmacology; D002536:Cerebral Arteries / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004195:Disease Models, Animal; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000975:Antioxidants; D002084:Butylated Hydroxytoluene; C081064:LY 231617